International law firm Bird & Bird advises Kainova Therapeutics, a clinical-stage biopharmaceutical company based in Montreal, Strasbourg and Boston, and a key player in innovative treatments for immuno-oncology and inflammation patients, on a first Series B round of CAD $32 million to accelerate the development of its immuno-oncology and inflammation portfolio.
The round was led by Investissement Québec, with continued support from existing investors CTI Life Sciences, Panacea Venture, 3B Future Health Fund, Seventure Partners, Viva BioInnovator, Turenne Capital, Schroders Capital, adMare BioInnovations and Seido Capital.
With this new funding, the biopharma plans to accelerate the clinical development of breakthrough treatments that precisely modulate G Protein-Coupled Receptors (GPCRs) to address unmet medical needs and improve therapeutic efficacy, particularly in immuno-oncology and inflammation. Currently operating in North America, France, and Australia, Kainova Therapeutics aims for global commercialization.
Bird & Bird regularly advises Kainova Therapeutics, formerly Domain Therapeutics, and notably assisted the biopharma in connection with its Series A.
Bird & Bird advised Kainova Therapeutics on this new transaction, with a team comprising partner Emmanuelle Porte, and associates Pascaline Sagot and Hugo Vallespi, for corporate matters.
Kainova Therapeutics was also advised by Fasken for Canadian law matters, with a team consisting of Guillaume Synnott, Partner, Camille Marceau and Frédéric Saint-Jean, Associates.
Investissement Québec was advised by Blakes in Canada.
